Drug Profile
Research programme: 2-Methoxyestradiol analogues - Cryptopharma
Alternative Names: 2-Methoxyestradiol analogues research programme - Cryptopharma; CP 2117; Pulmonary fibrosis therapy research programme - CryptopharmaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cryptopharma
- Class Estrenes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pulmonary fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in Australia
- 13 Jun 2005 Preclinical trials in Pulmonary fibrosis in Australia (unspecified route)